The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
about
Management of Multiple Sclerosis in the Breastfeeding MotherLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsNonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisThe HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide elementA model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study designPhysiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeuticsDevelopment of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab.Monitoring monoclonal antibody delivery in oncology: the example of bevacizumabA fully caninised anti-NGF monoclonal antibody for pain relief in dogsA pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patientsInfluence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models.Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modellingPharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous "manual syringe" injection or intravenously in women with HER2-positive early breast cancer.Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibodyBevacizumab for the treatment of glioblastoma.Antagonizing midkine accelerates fracture healing in mice by enhanced bone formation in the fracture callusA novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction.A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis.Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.Targeted drug delivery for cancer therapy: the other side of antibodies.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Immune checkpoint inhibitors in challenging populations.Quantitative measurement of the target-mediated internalization kinetics of biopharmaceuticalsSystems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.Neutralization of TNFSF10 ameliorates functional outcome in a murine model of Alzheimer's disease.In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT.Application of Pharmacokinetics Modelling to Predict Human Exposure of a Cationic Liposomal Subunit Antigen Vaccine System.Study and ICH validation of a reverse-phase liquid chromatographic method for the quantification of the intact monoclonal antibody cetuximab.Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.A FCGR3A Polymorphism Predicts Anti-drug Antibodies in Chronic Inflammatory Bowel Disease Patients Treated With Anti-TNF.Effects of an Unlabeled Loading Dose on Tumor-Specific Uptake of a Fluorescently Labeled Antibody for Optical Surgical Navigation.
P2860
Q26766337-C89FAEB9-421B-490F-94B0-899EC80CB20BQ26849243-BF7C6038-8D99-4C04-9F2E-52F0CB89A235Q30489162-AA7508EB-304C-4D61-9B31-71E50BDA9858Q33786815-6F7A3CCD-424D-4BCA-9D52-476AC84B6F9FQ34223916-F521EF48-1CCC-43E4-BC50-FEF1C7AE36DDQ34275537-0BAF62E2-D00C-42F1-ADE9-CA926212B478Q34291876-A81AE469-58BE-4E3F-BB81-929E5090830BQ34918726-66A7B820-8E18-4710-8B68-DA7EAEC8805DQ34951074-997EACB2-0ACF-401C-B838-0EB57CF0AD90Q35037390-D062311F-C72A-41CF-8402-258D87A3BFF2Q35193385-0BC66097-B7FC-4CB1-89CB-2904FACC1819Q35640448-FE15D3E9-F825-4D29-8FDD-ACAB52861F98Q35813114-5F287CC0-D89C-4EDD-9508-4E50F938E733Q35905876-B152C3F9-9D4F-446B-A664-173BF3E3801CQ35992515-34B03B04-F53E-479D-93EB-BC92EB5D6CB9Q36445944-20D8C4B3-BB65-4735-9DD7-140FF25C2DF3Q36644667-09F177DE-A43D-47D6-816D-828399C520ECQ36929502-582EB5A8-6F10-45DB-9071-C0AC498B4CFEQ37034753-CFB5F673-BEAF-42C8-82C4-D2FD0F27F8E6Q37335667-B97BC59A-5174-4A3B-8F1D-AFD8657C54CEQ37346118-F1705D2E-B19A-4BDA-87B6-EBB7A3E4E0CEQ37390483-B0A59C90-169F-44DD-B907-4D685F205E48Q37606966-8E2F8224-CE05-4C48-A666-DBBDBCA95E1AQ38058816-DD72D807-E708-4434-876E-E01D23485EBDQ38364462-CF976B2E-FBC8-49AF-85AE-31AAA76F9D48Q38831148-3A51DB54-E845-4F36-BF44-5FFDC0646DC0Q38939708-D673855C-2CD8-4ED2-BC46-F7E90EE8B32DQ38957698-E440A509-9810-4079-99A9-C9A38A593476Q38962519-41978FBF-33F3-40EB-B50D-0871E2AF7722Q40148689-B95538AE-6C0B-452F-B9F2-EE42C46868A0Q40961591-A1916B82-3B3C-435A-AF33-F40204C722D6Q41664475-2185BE29-C87C-45FC-ADC3-14DF32DAD608Q42424619-CEA0A367-1245-4217-94E4-18403AA5810CQ43019940-01737735-8A47-481C-92D4-3D9D9B9E54BDQ47351571-BA172FDE-6B6C-4F04-964A-FBEA620F8EDCQ48504497-EAAD7455-E8D2-436A-83BA-27C9BCE4C4B9Q49188389-7DF8F95E-6036-4EDF-B0CF-6151DB89FEC9Q49534303-21F4617A-5555-47F1-B86E-5ACE53B7257DQ54539778-EAB61B72-7723-46F4-918A-EDAE77345A8B
P2860
The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The pharmacokinetics and pharm ...... g applied to drug development.
@ast
The pharmacokinetics and pharm ...... g applied to drug development.
@en
type
label
The pharmacokinetics and pharm ...... g applied to drug development.
@ast
The pharmacokinetics and pharm ...... g applied to drug development.
@en
prefLabel
The pharmacokinetics and pharm ...... g applied to drug development.
@ast
The pharmacokinetics and pharm ...... g applied to drug development.
@en
P1476
The pharmacokinetics and pharm ...... ng applied to drug development
@en
P2093
Diane R Mould
Kevin R D Sweeney
P577
2007-01-01T00:00:00Z